There are 3 components inside PHESGO: PERJETA® (pertuzumab), Herceptin® (trastuzumab), and hyaluronidase. PERJETA and Herceptin are there to help treat the HER2-positive breast cancer, and the hyaluronidase is there to help them do that.
All the cells in the body—healthy and cancerous—have HER2 receptors. But HER2+ breast cancer cells have too many HER2 receptors, which makes them grow and divide faster than other types of cells.
PERJETA and Herceptin work together inside cells to block HER2 receptors. Each treatment is thought to block a different part of the HER2 receptor to help stop cells from growing and dividing into new cancer cells. Together, they build a stronger blockade. Because normal cells also have some HER2 receptors, targeted therapies may also affect them.
If you are already receiving Herceptin and PERJETA, as part of your breast cancer treatment via an infusion, you may be wondering how hours of infusion can be given in just minutes. It’s made possible by the use of hyaluronidase. Hyaluronidase is a protein naturally found in most tissues of the body.
Hyaluronidase helps enhance the way the body absorbs medicines injected under the skin. When PHESGO is injected, the hyaluronidase makes the tissue under the skin more absorbent temporarily so that it’s able to receive the medication.
Once it’s absorbed by your body, the PERJETA and Herceptin inside PHESGO are thought to work the same way to treat your HER2+ breast cancer.
PHESGO® (pertuzumab, trastuzumab, and hyaluronidase-zzxf) is a prescription medicine approved for use in combination with chemotherapy for:
PHESGO is a prescription medicine approved for use in combination with docetaxel in adults who have HER2-positive breast cancer that has spread to different parts of the body (metastatic) and who have not received anti-HER2 therapy or chemotherapy for metastatic breast cancer.
PHESGO may cause heart problems, including those without symptoms (such as reduced heart function) and those with symptoms (such as congestive heart failure).
Receiving PHESGO during pregnancy can result in the death of an unborn baby and birth defects.
PHESGO may cause serious lung problems.
The most common side effects of PHESGO when given with chemotherapy as part of an early breast cancer regimen are:
The most common side effects of PHESGO when given with docetaxel for treatment of breast cancer that has spread to other parts of the body (metastatic) are:
You are encouraged to report side effects to Genentech and the FDA. You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at 1-888-835-2555.
Talk to a healthcare professional for more information about the benefits and risks of PHESGO.
Please see full Prescribing Information for additional Important Safety Information, including most serious side effects.
If you cannot afford your medication, visit phesgo.com/financial-support for financial assistance information.
The information contained in this section of the site is intended for U.S. healthcare professionals only. Click "OK" if you are a healthcare professional.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.